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ABSTRACT

This thesis project incorporates the principles of rational and computer aided drug
design in the quest for an improved anti-malarial agent. The target, a pathway for
isoprenoid biosynthesis (the deoxy-D-xylulose-5-phosphate (DOXP) pathway)
occurs in the parasite plastid – the apicoplast, and among the factors that make it
an excellent target for an anti-malarial agent is its uniqueness from the pathway in
the host, thus accounting for its specificity and low toxicity. A library of 18
potential anti malarial analogues/ ligands were designed and tested in silico against
the receptor using molecular docking.
The analogue L ο (omicron) - {3-[acetyl(hydroxy)amino]-1-hydroxypropyl}
phosphonic acid was found to be the most promising anti malarial analogue and it
may be worthwhile to subject the molecule to further analysis and comprehensive
evaluation.
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1. Introduction
Malaria, a parasitic disease typified by a series of fever paroxysms, is one of the
oldest and most prevalent of diseases known to mankind (Bradley et al.). Until
as recently as the early 20th century, the cause of malaria was unknown, with
common belief being that it was caused by the release of poisonous gases at
night from tainted soil. Incidentally, this was how the disease got its name,
‘malaria’ being the French transliteration of ‘bad air from the swamps’,
although we now know malaria to be a parasitic disease borne by an insect
vector. In spite of a century of effort towards eradicating this disease, it
continues to be endemic throughout much of the tropics and subtropics
(Figure 1) as these areas provide ideal breeding and living conditions for the
insect vector, the female Anopheles mosquito.

Figure 1: Geographic distribution of malaria
Source: www.cdc.gov
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Approximately 40% of the world's population lives in these affected areas and
are at risk of infection. Over 500 million new cases are recorded each year,
resulting in an estimated 1.5 million to 2.7 million fatalities every year (WHO
Fact sheet, 2007). These epidemiological data are staggering for a disease that
had once been effectively eradicated in many parts of the world and partially
eliminated in others.
The fact that malaria has been a scourge of mankind since ancient times is
evident from some of the earliest known medical writings from Assyria, India
and China that describe malaria-like intermittent fevers with reasonable
accuracy. Hippocrates has been credited with the earliest description of the
clinical symptoms in 500 BC, more than 2000 years before Charles Laveran,
Ronald Ross and Camillo Golgi described the parasite in late 19th century
(Wiser, 2000). The modern scientific and medical community now knows
malaria to be a potentially life threatening and complex multi-system disease
affecting erythrocytes, the liver, brain, kidneys, placenta and other tissues.
1.1 The Malarial Pathogen
The pathogenic organism implicated in malaria is an obligate unicellular
protozoan parasite of the genus Plasmodium. They are intracellular eukaryotic
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microbes belonging to the phylum apicomplexa and exhibit a heteroxenous life
cycle involving an arthropod vector and a vertebrate host (Wiser, 2000).
Four species of plasmodium (Plasmodium falciparum, Plasmodium vivax, Plasmodium
ovale, Plasmodium malariae) are known to cause malaria in humans. The species of
plasmodium differ vis-à-vis their morphology, details of their life cycles, and
clinical manifestations. P falciparum and P vivax account for the vast majority of
cases, with P falciparum causing the most severe form of the disease and being
responsible for 95% of all malaria deaths worldwide.
The lifecycle of the plasmodium species is complex (Figure 2), alternating
between two organisms, namely the insect vector and the vertebrate host. The
parasite undergoes three phases of asexual reproduction (two in the host and
one in the vector) and one phase of sexual reproduction in the vector.
In summary, the malaria parasite exhibits a life cycle typical to apicomplexan
organisms. The sporozoite, merozoite and ookinete are the three invasive
stages, which are characterized by apical organelles that aid in the invasion of
host cells. Two stages of asexual replication (merogony) are observed. The first,
occurs in the liver and is called exo-erythrocytic schizogony (asexual replication
of the schizonts). The resulting merozoites then invade erythrocytes and initiate
another stage of asexual replication called erythrocytic schizogony. Some of
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these merozoites undergo gamete formation (gamogony). The sexual forms
(gametes) are then taken up by a feeding anopheles mosquito, and then fuse to
become a zygote in the mosquito gut wall. The zygote develops into an
ookinete and then an oocyst followed by sporogony, producing sporozoites,
which after traveling to the salivary glands infect another human host thus
continuing the cycle.

Figure 2: The life cycle of malaria (please see legend)
Source: www.cdc.gov
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Legend for figure 2 (Source: www.cdc.gov):
The sporozoites are injected into the human host by an infected female Anopheles mosquito , which
and mature into schizonts . The schizonts then rupture, releasing
then infect the liver cells
merozoites . The initial replication in the liver (exo-erythrocytic schizogony ) is followed by
asexual multiplication in the erythrocytes (erythrocytic schizogony ). The merozoites infect red
blood cells . Some of the ring stage trophozoites mature into schizonts, which release merozoites
on rupturing , while others differentiate into sexual erythrocytic stages (gametocytes) . The
blood stage parasites are responsible for the clinical manifestations of the disease. The Anopheles
mosquito ingests the male (microgametocytes) and female (macrogametocytes), during a blood meal
. The parasites’ multiplication in the mosquito is referred to as the sporogonic cycle . The
microgametes enter the macrogametes, within the mosquito's stomach, producing zygotes . The
zygotes become elongated and motile (ookinetes) . They invade the midgut wall of the mosquito
and develop into oocysts . The oocysts grow, rupture, and release sporozoites , which make
their way to the mosquito's salivary glands. The sporozoites are inoculated into a new human host
thus perpetuating the malaria life cycle.

1.2 Clinical Manifestations of Malaria and Pathogenesis
The asexual erythrocytic stage parasites are almost entirely responsible for most
of the clinical manifestations associated with malaria (Wiser, 2000). The most
striking feature of the plasmodium infection is an acute febrile illness, which is
particularly notable for its periodic fever paroxysms occurring at either 48 or
72-hour intervals. The severity of the attacks depends on various factors
including species of plasmodium and immunity of the patient. The typical
prepatent* periods vary slightly according to species ranging from 6 to 18 days,
while the incubation** periods tend to be a little longer and ranges from 6 to 40
days. 'Flu-like' prodromal symptoms such as headache, slight fever, muscle pain
etc. are known to precede the first febrile attack.
*

The prepatent period is the time between sporozoite inoculation and appearance of parasites in the blood.
The incubation period is defined as the time between sporozoite inoculation and onset of symptoms.

**
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The febrile paroxysms exhibit periodicities of 72 hours for P.malariae and 48
hours for the other three species. In the case of P. falciparum infections
however, it is not uncommon to observe a continuous fever or irregular attacks
instead of periodic paroxysms.
A typical malarial paroxysm usually lasts for 4-8 hours and begins with a
sudden onset of chills. The patient despite having an elevated temperature
experiences an intense feeling of cold. This “cold stage” is characterized by a
vigorous shivering. This is followed by the “hot stage” during which the patient
feels an intense heat accompanied by other symptoms such as headache,
fatigue, dizziness, and nausea. A period of profuse sweating generally follows
the hot stage as the fever begins to decline and the patient often does not
experience any other symptoms until the onset of the next paroxysm.
The periodic fever in all kinds of malaria is a result of the rupture of the
infected erythrocytes and the subsequent release of merozoites. A unique
feature of the parasite is its intracellular location, where it shares a close
relationship with its host causing several deleterious consequences, which can
be described at the cellular and molecular levels. In the case of falciparum
malaria (the most lethal form), infected erythrocytes adhere to the endothelium
of capillaries and post capillary venules, leading to obstruction of the
microcirculation and in turn to local tissue anoxia. In the brain this causes
6

cerebral malaria, a form of encephalopathy characterized by impaired
consciousness. The typical symptoms of cerebral malaria are severe headache
followed by drowsiness, confusion, and ultimately coma. Convulsions are also
frequently associated with cerebral malaria. In the kidneys, this cytoadherence
may cause acute tubular necrosis and renal failure, and in the intestines it can
lead to ischemia and ulceration causing gastrointestinal bleeding. Severe anemia
may also be caused due to the massive hemolysis as a result of the large-scale
destruction of the erythrocytes and phagocytosis of infected erythrocytes.
1.3 Host Defenses
Various hereditary and acquired factors are known to regulate susceptibility to
malaria infection and disease to a certain extent (Crutcher & Hoffman, 1996).
Certain genetic diseases such as sickle cell anemia have been associated with
decrease in the incidence of disease (Bradley et al.). Although the malarial
parasite can infect individuals with the sickle cell trait, such individuals rarely
manifest malaria since the parasite does not develops well in their erythrocytes.
Other genetic variations that protect against malarial infection or disease
include the absence of the Duffy blood group antigen in many populations in
Africa and ovalocytosis*. The Duffy antigen functions as the erythrocyte
surface receptor for P. vivax merozoites; thereby precluding parasite invasion in
*

an inherited condition characterized by slightly oval or elliptical RBCs
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its absence. Similarly individuals with ovalocytosis, possess a more merozoite
resistant erythrocyte membrane as a result of a mutation in band 3 (an
erythrocyte membrane protein).
Acquired immunity has also been observed in areas of heavy malaria incidence.
However, the recurrent infections do not confer sterile protective immunity
against malaria but rather help reducing the severity of the disease through
development of humoral and cellular immune responses against the various
stages of the parasite.
1.4 Combating malaria
The broad strategies to fight malaria could be outlined as follows:
• Targeting the mosquito, the vector (carrier) of the parasite.
• Development of a vaccine that offers immunity against the parasite.
• Targeting the parasite through drugs that disable it.
Vector control:
Several well-conducted campaigns had been conducted in the previous century
that targeted at controlling the vector (the anopheles mosquito) population.
However over time, factors such as laxity in anti-malarial campaigns, and
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emergence of insecticide resistant strains of the vector caused malaria to stage a
dramatic comeback in spite of its near eradication in the early mid-sixties.
Immunization:
While immunization is an alternative that many groups are working on, the
path to designing a single vaccine that can provide long-term immunity against
the parasite seems to be fraught with obstacles. Among the various problems
encountered is the genetic complexity of the parasite, which means that each
infection presents thousands of antigens to the immune system. The parasite
also rapidly passes through several stages while in the human host, presenting a
different set of molecules for the immune system to combat at each stage. And
finally, it is also possible to have multiple malaria infections of not only
different strains but also of different species at the same time. All these factors
make the development of an anti-malarial vaccine a tremendous challenge.
Chemotherapy:
Traditionally, drugs were identified and developed empirically, and though
native medical practice and folk tradition provided the occasional insights, it
was often driven by serendipity. For instance, this was how quinine was found
to be useful. The colonial British, having heard about the anti-malarial
properties of the extract of the bark from the cinchona trees of East Indies
9

investigated it and discovered the drug molecule. With the advances made in
biology, chemistry and other related sciences, drug discovery and development
have become much more rational and systematic.
1.5 History of Anti-Malarial Drug Development
The earliest drug effective against malaria has been quinine, which has been in
use since the 16th century. Over the years, however, it has lost its effectiveness
in many parts of the world since the plasmodium parasites have evolved genetic
variants resistant to it. An isomer of quinine called quinidine has been used
occasionally in cases of cerebral malaria. Other and better drugs of the
quinoline class, such as the aminoquinolines have been developed during the
past five decades, but the emergence of resistant strains of the parasites against
most of the commonly used drugs, such as the formerly effective and widely
used chloroquine, has plagued the war against malaria (Jain, 2002). While newer
drugs such as pyrimethamine and sulphadoxine that were brought onto the
scene, did provide some alternatives, the relief was short lived, as the everingenious parasite soon churned out strains resistant to them as well. In an
attempt to handle this problem, combination therapies were chalked out, which
are still being used, but resistance to these regimes has also been reported. As
an unfortunate side effect, all of this experimentation with different drug
therapies has given birth to the single largest and most potent malaria threat
10

today, namely multi-drug resistant P falciparum. Among the latest additions to
the anti-malarial armory is a new class of compounds, artemisinin and its
derivatives. These are a safe class of drugs and do not suffer from widespread
resistance (at least not yet), but are plagued by their own set of problems like
poor bioavailability, high incidence of recrudescence*, and action limited to
specific stages of Plasmodium.

*

Recrudescence is a fall in the level of parasite population below diagnostic levels followed by a later
increase (Wiser, 2000).
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2. Objectives
As stated in the research proposal this project endeavored to
• Perform an up-to-date literature survey
An up-to-date literature survey of anti-malarial research would help
uncover recent advances in the field, thereby identifying potential issues
of interest. Furthermore, considering the rapid advances in the area such
as sequencing of the genomes two of the plasmodium species,
increasingly promising targets are being uncovered. The literature survey
would also aid in sifting through various potential drug targets and
choosing the most promising one.
• Design anti-malarial analogues
Computational tools such as ACD Chemsketch will be employed to
design a group of analogues / ligands that would possess the capacity to
inhibit critical components of parasite biochemistry.
• Perform Docking studies
A comparative evaluation of the designed anti-malarial ligands will be
conducted using molecular modeling and simulation techniques such as
Docking.
12

3. Recent Developments – A literature survey
3.1 Cracking of the vivax code
One of the most recent developments in the battle against malaria; as reported
in the Oct 9th issue of Nature (2008, vol. 455); has been the cracking of the
genetic code of P vivax, which is responsible for 40% of the all malaria
infections worldwide (Carlton et al., 2008). This is the second species of
Plasmodium to have its genome sequenced after P falciparum in 2002. This
landmark event was achieved by a group of international researchers at
different institutes, led by Dr. Jane Carlton of the NYU Langone Medical
Center. The project had been underway for a total of six years and involved
researchers from England, Spain, Australia, Brazil and the United States.
As with the revelation of the falciparum genome, this new information could
be expected to expose other chinks in the armor of the malarial parasite. The
next steps would be to sequence the other P. vivax genomes (from Brazil,
Mauritania, India, North Korea and Indonesia) and to identify novel vaccine
candidates and consequently generate an evolutionary map of the species.
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3.2 New targets for anti-malarial agents
As our understanding of this ancient disease is constantly improving with
advances in various technologies; new drug/vaccine targets are constantly being
uncovered and evaluated.
3.2.1 PfEMP1

The Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a
parasite protein that has been found on the surfaces of infected erythrocytes of
the host. These cause the surface of the RBC to become sticky and thus adhere
to the vascular endothelium. This phenomenon is referred to as cytoadherence
and is observed only in falciparum malaria. It allows the parasites in the
infected and sticky RBC to avoid spleen-mediated destruction. It is also this
event that is responsible for the extremely deadly ‘cerebral malaria’, in which
case the infected cells cluster in the narrow blood capillaries in the brain
causing coma and subsequently brain death.
Although these sticky proteins had been studied and evaluated before, it was
believed that they would make difficult targets since they were encoded by the
highly variable var gene family. However, the variable region of the PfEMP1
moves aside to allow the anchoring of the hidden conserved binding region to
the blood vessel walls. This event is caused by an interaction with chondroitin
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sulphate; a component of the blood vessel walls. Recent studies (Higgins, 2008)
indicate that pharmaceutical agents mimicking chondroitin sulphate might be
able to trigger a structural response in the protein causing it to reveal it’s
conserved binding domain thus hastening an immune response to these
proteins.
3.2.2 PfSUB1

The Plasmodium falciparum subtilisin-like protease

(PfSUB1) is an enzyme

involved in the propagation of the parasites within the host. Although
researchers were aware of the existence of the protein for almost a decade, its
role has now come to light at the National Institute for Medical Research
(Yeoh et al., 2007).
Inside the host, the parasite divides within an intraerythrocytic parasitophorous
vacuole, which eventually ruptures and releases merozoites, which go on to
invade fresh erythrocytes and continue the cycle. Just before the rupture and
release of the new merozoites, the PfSUB1 is discharged from ‘exonemes’
(previously unrecognized organelles) into the vacuole space. The enzyme plays
a critical role in destroying the existing cell structures, thus allowing the parasite
to escape and infect other cells.
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The researchers at NIMR have identified a plant-derived molecule that was able
to inhibit the PfSUB1 enzyme, thus preventing the merozoites from escaping
and continuing the vicious cycle.
3.2.3 The Apicoplast

The Apicoplast is a relatively recent discovery (Foth & McFadden, 2003) and
has been the object of close scrutiny for several reasons. This curious organelle,
found in parasites belonging to the phylum Apicomplexa, is homologous to
chloroplasts of plant and algal cells and is prokaryotic in origin. The presence
of a prokaryotic target in Plasmodium comes as a boon to the anti-malarial
crusade, opening up a whole new avenue of drug targets, as the host and the
plastid metabolic pathways are sufficiently different to allow differential
inhibition. The biosynthesis of isoprenoids (involved in many vital processes
such as the electron transfer system and signal transduction) is one of the
essential metabolic functions of the apicoplast. While humans rely on a
mevalonate-dependent pathway for their isoprenoids, the apicoplast produces
isoprenoids through the Deoxy Xylulose-5-Phosphate (DOXP) pathway
(Figure 3) (Lichtenthaler, 2000), (Takahashi et al., 1998). Thus the uniqueness
and significance of the DOXP pathway to parasite metabolism causes it to be
an excellent target (Lichtenthaler et al., 2000) for the design of an anti-malarial
agent, which is both highly specific and minimally toxic.
16

Figure 3: The DOXP pathway for isoprenoid biosynthesis*
Source: Adapted from Lichtenthaler, 2000

*

All two dimensional structures in this document were drawn using ACD/ChemSketch; a tool by
Advanced Chemistry Development, Inc. (ACD/ChemSketch Freeware, 2008)
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4. Materials and Methods
4.1 Inhibitors of the DOXP pathway
Fosmidomycin, initially developed in 1970’s as an herbicide, was later
discovered to possess anti malarial activity by virtue of its capacity to inhibit
deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) of the DOXP
pathway (Jomaa et al., 1999). In vitro tests have shown that both fosmidomycin
and a methylated analogue FR900098 inhibited growth of P.falciparum by
inhibiting the second enzyme of the DOXP pathway, viz. deoxy-D-xylulose-5phosphate reductoisomerase (DXR) which is responsible for the conversion of
DOXP, the substrate to 2-methyl-D-erythritol 4-phosphate.
Fosmidomycin and its analogue FR-900098 (Figure 4) competitively inhibit
DXR due to their structural similarity to the natural substrate deoxy-Dxylulose-5-phosphate.

Figure 4 (a): Fosmidomycin

Figure 4 (b): FR-900098

Since the DOXP pathway is absent in mammals, fosmidomycin and FR-900098
are known to have low toxicity. The lethal doses in rats are above 8000 and
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5000 mg/kg after oral and subcutaneous administration, respectively. Their
anti-malarial activity was tested in a murine model infected with the lethal P.
vinckei, a rodent malaria parasite (Jomaa et al., 1999). The animals were treated
with the drugs from day 1 after infection to 4 days later. The drugs were well
tolerated, even at dosages as high as 300 mg/kg. Untreated control animals
developed parasitemias on day five and died on day seven after infection.
Animals treated with dosages of >10 mg/kg of fosmidomycin, or 5 mg/kg of
FR-900098 appeared to be free of parasites. However recrudescence was
observed when the treatment was terminated after 4 days. The efficiency of
these drugs at low dosages and their activity after oral administration
demonstrate that fosmidomycin and FR-900098 are potential anti-malarial
drugs. The efficacy of fosmidomycin and its derivatives against multi drugresistant parasites, and high stability make them attractive as a potential new
class of anti-malarial drugs.
Clinical testing of this drug has proven it to be effective and safe (Lell et al.,
2003), although the occurrence of recrudescence is driving developers to
produce improved analogues of the drug. As part of an earlier in silico activity
(Thovarai & Mehta, 2004) a small group of analogues have been designed and
studied preliminarily.
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4.2 Design of novel analogues as inhibitors of the DOXP pathway
A compact library of 18 compounds was designed while keeping in
consideration the data obtained from SAR (Structure Activity Relationship)
studies of fosmidomycin conducted at the Max-Planck Institute (Steinbacher et
al., 2003).
The SAR studies reveal the following:
• The phosphate group of the ligand is responsible for anchoring it to the
receptor site and is therefore indispensable.
• (N-formyl-N-hydroxy) amino groups provides two electron withdrawers
(oxygen molecules) essential for interaction.
• Both the above sites are connected by a spacer of three methylene
groups which confer the flexibility required by the ligand to fit into the
receptor pocket.
The inhibitor (fosmidomycin) shows a high degree of similarity to the substrate
(Figure 5), which emphasizes the above three criteria for binding to the
receptor, as outlined by the SAR studies. All structures of the potential anti malarial molecules would be required to incorporate these relevant molecular
properties/features of the inhibitor (fosmidomycin) or the substrate (DOXP)
or both.
20

Figure 5: Comparison of the structures of DOXP (substrate - blue) with
fosmidomycin (inhibitor - red)

A library of analogues (Table 1) was selectively designed with the inhibitor and
the substrate as models with the objective of minimizing structural redundancy
and irrelevant data in the form of structures with properties non-conducive to
receptor binding.
S no.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Analogue name
L α (alpha)
L β (beta)
L γ (gamma)
L δ (delta)
L ε (epsilon)
L ζ (zeta)
L η (eta)
L θ (theta)
L ι (iota)
L κ (kappa)
L λ (lamda)
L µ (mu)
L ν (nu)
L ξ (xi)
L ο (omicron)
L π (pi)
L ρ (rho)
L σ (sigma)

IUPAC name
4-oxopentyl dihydrogen phosphate
4-hydroxy-5-oxopentyl dihydrogen phosphate
3-[formyl(hydroxy)amino]propyl dihydrogen phosphate
3-[acetyl(hydroxy)amino]propyl dihydrogen phosphate
5-oxopentyl dihydrogen phosphate
3-hydroxy-4-oxopentyl dihydrogen phosphate
4-hydroxy-5-oxohexyl dihydrogen phosphate
4-oxopentylphosphonic acid
4-hydroxy-5-oxopentylphosphonic acid
4-hydroxy-5-oxohexylphosphonic acid
(1-hydroxy-5-oxopentyl)phosphonic acid
(5-hydroxy-6-oxohexan-2-yl)phosphonic acid
(1-hydroxy-4-methyl-5-oxopentyl)phosphonic acid
(1-hydroxy-4-methyl-5-oxohexyl)phosphonic acid
{3-[acetyl(hydroxy)amino]-1-ydroxypropyl}phosphonic acid
{4-[acetyl(hydroxy)amino]butan-2-yl}phosphonic acid
2-[acetyl(hydroxy)amino]ethyl dihydrogen phosphate
2-[formyl(hydroxy)amino]ethyl dihydrogen phosphate

Table 1: Compact library of potential anti malarial analogues (L: Ligand)
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Complete structures can be found in Appendix A. The 2D structures of the
analogues were designed using the software ACD/ChemSketch.
4.3 The receptor /target
The 2nd enzyme of the DOXP pathway, the deoxy-D-xylulose-5-phosphate
reductoisomerase (DXR) serves as the target in this case. The primary step
towards any related molecular modeling study would be the identification of
the structure of DXR. The Protein Data Bank (www.pdb.org) returned several
entries for the reductoisomerase, most of them having E. coli as their source. It
was noted that some of the recently identified structures had been crystallized
in complex with fosmidomycin. Such a structure is an obvious choice for future
studies as it contains within it the necessary information about the relevant
active site.
The single chain PDB structure, 1Q0L (Mac Sweeney et al., 2005), was selected
for further studies among the most recently elucidated reductoisomerase
structures. The PDB structure 1Q0L, is the crystal structure of E.coli 1-deoxyD-xylulose-5-phosphate reductoisomerase in a complex with the antimalarial
compound fosmidomycin and NADPH.
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Figure 6a: Wireframe model of PDB id 1Q0L (Mac Sweeney et al., 2005)
Source: WebMol viewer at www.pdb.org

Figure 6b: Backbone of PDB id 1Q0L (Mac Sweeney et al., 2005)
Source: Protein Workshop viewer at www.pdb.org
23

4.4 Docking studies
As mentioned earlier one of the objectives of this project is to study the
interactions between the target receptor and designed analogues in silico in an
attempt to identify potentially promising anti-malarial analogues. One of the
techniques available today to achieve this is using a molecular modeling
simulation called Molecular Docking (Kitchen et al., 2004).
A molecular docking simulation is essentially a search for the best or most
optimum ligand–receptor complex. The optimization is achieved by minimizing
the interaction energy between the molecules under study. The simulation
algorithms generally search through conformational space to isolate complexes
with the lowest interaction energy. The low interaction energy is an indication
of the stability and hence viability of the complex. The tool used for all docking
operations in this study is the DockingServer (Bikadi et al.).
The DockingServer (www.dockingserver.com) is a web-based service that
facilitates docking of ligands to receptor proteins by calculating the site of
interaction, geometry and associated energy of ligands / small molecules
interacting with proteins. In addition to docking, the interactions between the
molecules can also be analyzed. DockingServer is developed and maintained by
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Virtua Drug Ltd and free access is available for academic users without
registration using a guest account and a common workspace.
4.5 Steps and methods involved in docking operations
4.5.1 Ligand preparation

After the design and generation of the ligand molecules, they were further
converted into .mol files (using ChemSketch) and uploaded to the
DockingServer.
Once uploaded, the ligand molecules were prepared for the docking process.
This consisted of minimizing the energy of the molecule using the Dreiding
force field (Mayo et al., 1990) followed by optimizing its geometry and
calculation of partial charges using semi empirical methods (Stewart, 2007). The
energy minimization and optimization are performed to find a local energy
minimum or in other words a state of equilibrium configuration of the
molecule under study.
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Figure 7: Setting Ligand parameter prior to Docking
4.5.2 Protein preparation

The 3 dimensional protein structure of the receptor 1-deoxy-D-xylulose-5phosphate reductoisomerase was downloaded from the Protein Data Bank at
rcsb.org. The pdb structure file (1Q0L) was uploaded to the Docking server
and processed for docking. The simulation box (area in which the docking was
to occur) was selected and confirmed.
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Figure 8a: Processing protein – selecting the simulation box

Figure 8b: Processing protein – simulation box

27

4.5.3 Docking

The preprocessed ligand and protein are finally selected and set up for docking.
The Docking Server uses the tool “AutoDock 4.0” for the docking simulations.
AutoDock 4.0 uses the LGA (Lamarckian genetic algorithm) for the docking
(Morris et al., 1998) and the Solis and Wets local search method to determine the
optimum complexes (Solis & Wets, 1981).

Figure 9: Flowchart of a typical Lamarckian Genetic Algorithm
Source: Adapted from www.iem.bham.ac.uk
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The Lamarckian Genetic Algorithm is based on Lamarckian inheritance, rather
than Darwinian. Thus acquired characteristics of an organism (an individual in
the population) are passed on to the next generation of individuals along with
the results of mutations and crossovers.
The Solis and Wets local search method can be described as hill-climbing
algorithm with a step size that is adaptive (Rosin et al., 1997). The algorithm
starts at a randomly chosen point x in the given search space. A deviate d is
assigned which is governed by parameter p. The algorithm then moves through
the various values of x and if either x+d or x-d is better, a move is made to that
point and it is recorded as a ‘success’. A ‘failure’ is recorded if this is not so.
The parameter p is varied according to the number of successive ‘successes’ or
‘failures’, thereby controlling the speed with which the search progresses. For
instance, p is increased after several consecutive successes, which increases the
value of d. Thus the steps x+d will be larger and the search faster. Alternatively
the steps x-d will be smaller thus focusing the search.
The parameters for the docking operation (as shown in figure 10) are:
• tstep: Translational step. It is the distance of each translational step in
the search space. It was set to a value of 0.2 Å.
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• qstep: Quaternion step. It is the angle of each quaternion rotation in the
search space. The quaternion rotations were used to implement rigid
body orientation of the ligand. It was set to a value of 5°.
• dstep: Torsion step. It is the angle of each torsional step passing through
the search space. It was set to a value of 5°.
• rmstol: Root mean square deviation tolerance. In order to rank the
various ligand conformations, a cluster analysis or `structure binning' is
performed. This analysis is based on the positional root mean square
deviation (rmsd) of corresponding atoms. The rmstol value is a
threshold value and is set to 2 Å. For instance, two conformations
having an rmsd lower than the rmstol value are stored in the same
cluster.
• ga_pop_size: The population size of the Lamarckian Genetic Algorithm.
It is set to a value of 150.
• ga_num_evals: The number of energy evaluations after which the
Lamarckian Genetic Algorithm was set to terminate. It is set to a value
of 250000.
• ga_num_generations: The number of generations in each run of the
Lamarckian Genetic Algorithm. It is set to a value of 540000.
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• ga_run: The number of runs of the Lamarckian Genetic Algorithm. It is
set to a value of 2.

Figure 10: Docking parameters

The docking output also included the following text with respect to parameters
used:
“Initial position, orientation, and torsions of the ligand molecules were set
randomly. Each docking experiment was derived from 2 different runs that
were set to terminate after a maximum of 250000 energy evaluations. The
population size was set to 150. During the search, a translational step of 0.2 Å,
and quaternion and torsion steps of 5 were applied.”
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5. Results
5.1 Comparison of interactions
The first molecules to be docked were the inhibitors Fosmidomycin and
FR900098. The rationale being to use them as benchmarks against which the
rest of the new analogues would be evaluated.
Est. Free Energy of
Binding (kcal/mol)
Fosmidomycin -1.42
FR900098
-1.26
L α (alpha)
-0.68
L β (beta)
-0.04
-0.26
L γ (gamma)
L δ (delta)
-0.28
L ε (epsilon)
-0.75
-0.14
L ζ (zeta)
L η (eta)
-0.97
L θ (theta)
-0.77
L ι (iota)
-1.15
L κ (kappa)
-1.15
L λ (lamda)
-2.19
L µ (mu)
-1.64
L ν (nu)
-2.35
L ξ (xi)
-2.49
L ο (omicron) -2.65
L π (pi)
-2.13
L ρ (rho)
-1.01
L σ (sigma)
-0.14

Analogue

Est. Inhibition
Constant, Ki (mM)
90.34
118.62
315.99
929.24
643.25
621.69
282.49
786.58
193.71
270.68
142.39
142.76
24.97
62.45
18.91
15.03
11.48
27.67
182.11
793.21

Table 2: Comparison of Binding energies and Ki of analogues

As observed in Table 2, six of the original 18 analogues display better binding
energies and inhibition constants than the actual inhibitor, fosmidomycin.
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5.2 Closer view of select individual interactions
5.2.1 Fosmidomycin – 1Q0L

Figure 11a: Fosmidomycin to 1Q0L - Results table and interacting residues

Figure 11b: Fosmidomycin to 1Q0L – Rendering of interaction
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5.2.2 L Lamda – 1Q0L

Figure 12a:L Lamda to 1Q0L - Results table and Interacting residues

Figure 12b: L Lamda to 1Q0L – Rendering of interaction
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5.2.3 L Mu – 1Q0L

Figure 13a: L Mu to 1Q0L - Results table and Interacting residues

Figure 13b: L Mu to 1Q0L – Rendering of interaction
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5.2.4 L Nu – 1Q0L

Figure 14a: L Nu to 1Q0L - Results table and Interacting residues

Figure 14b: L Nu to 1Q0L – Rendering of interaction
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5.2.5 L Xi – 1Q0L

Figure 15a: L Xi to 1Q0L - Results table and Interacting residues

Figure 15b: L Xi to 1Q0L – Rendering of interaction
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5.2.6 L Omicron – 1Q0L

Figure 16a: L Omicron to 1Q0L - Results table and Interacting residues

Figure 16b: L Omicron to 1Q0L – Rendering of interaction
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5.2.7 L Pi – 1Q0L

Figure 17a: L Pi to 1Q0L - Results table and Interacting residues

Figure 17b: L Pi to 1Q0L – Rendering of interaction
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5.3 Comparison of the optimum interactions
The six best interactions were more closely evaluated by comparing interaction
tables supplied by Docking server.
Analogue
Fosmidomycin
L λ (lamda)
L µ (mu)
L ν (nu)
L ξ (xi)
L ο (omicron)
L π (pi)

H bond
0
0
0
0
1
0
1

Polar
2
2
1
1
0
4
5

Hydrophobic
1
2
2
1
2
3
4

Other
9
6
11
6
5
9
5

Table 3: Comparison of number of interactions of analogues with receptor

These six optimum interactions represent the most promising anti-malarial
analogues. As observed in table 2, the analogue omicron possesses the lowest
binding energy (-2.65 kcal/mol) and lowest inhibition constant (11.48 mM).
Once again as observed in Table 3 the analogue omicron possesses the largest
number of interactions with the receptor thereby further supporting evidence
that it is most likely to have superior anti-malarial activity.
5.4 L ο (omicron)
The analogue L omicron is an analogue of fosmidomycin and it combines
features of both inhibitors (fosmidomycin and FR900098) as well as the
substrate (DOXP) as seen in figure 18.

40

Figure 18: Analogue L Omicron
IUPAC name: {3-[acetyl(hydroxy)amino]-1- hydroxypropyl}phosphonic acid

Figure 19: Interaction table of Omicron with receptor 1Q0L

Figure 19 depicts the various residues of the DXR enzyme that analogue
omicron interacts with.
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6. Discussion
Malaria has plagued mankind since ancient times and though it had been largely
contained in some parts of the world and eradicated from the temperate
regions, factors such as emergence of drug/insecticide resistant strains of the
parasite and the vector have caused it to re-emerge as a growing threat
especially in the developing nations.
The project integrates the target-oriented specificity of the rational drug design
approach with the cutting-edge simulation technology of computational drug
design, in the quest for an improved anti-malarial agent. The target, isoprenoid
biosynthesis in the parasite, was selected from among other newly uncovered
targets, which have stemmed from a better understanding of certain unique
features of the parasite biology, after recent developments such as the
sequencing of the P. falciparum and P. vivax genome and the discovery of the
presence of a plastid in the parasite.
The pathway for isoprenoid biosynthesis (the deoxy-D-xylulose-5-phosphate
(DOXP) pathway) occurs in the parasite plastid – the apicoplast, and among
the factors that make it an excellent target for an anti-malarial agent is its
uniqueness from the pathway in the host, thus accounting for its specificity and
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low toxicity. The focus of the project has been on developing inhibitors to
DOXP reductoisomerase (DXR), the second enzyme in the DOXP pathway.
The structure of the E. coli DOXP reductoisomerase (1Q0L) was chosen as a
receptor for further simulation studies as it was in complex with fosmidomycin
and possessed the requisite active site information.
A library of 18 potential inhibitor molecules was designed on the basis of the
results from the SAR studies of fosmidomycin - a known inhibitor. The
molecules were modeled on structural properties of both the inhibitor and the
substrate (which are structurally similar to each other). The objective of
selectively designing a library of analogues with the inhibitor and the substrate
as models is to minimize structural redundancy and avoid irrelevant data in the
form of structures with properties non-conducive to receptor-binding.
The interactions of designed analogues with the protein receptor were then
analyzed using the online molecular modeling tool DockingServer. The
interaction energy values of the ligand molecules were observed and compared
to those of a pre-existing inhibitor molecule (fosmidomycin) as well as to those
of each other. Some of these comparisons were favorable and indicated the
higher binding affinity of the designed analogues to the receptor than
fosmidomycin.
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It must be noted however that the above research, conducted solely using tools
of computer aided drug design, is by no means a substitute to the practical, in
vitro or clinical evaluation of the designed and selected drug molecule. What this
project attempts to achieve is a minimization of the randomness of the
research: by focusing on a specific target and secondly, a significant reduction
in utilization of resources: by in silico elimination of most of the unfit analogues
in favor of the most promising drug candidate. Thus practically speaking,
instead of the synthesis of 18 different compounds followed by their in vitro / in
vivo evaluation, which is expensive (both financially and in terms of time); this
research filters out (using molecular modeling software) most of the structures,
producing the one analogue (L Omicron) that seems to be most promising.
In conclusion, it is worthwhile to comment on possible follow-ups or future
directions this thesis could take. A similar study on a larger and more random
(as opposed to the focused approach described here) set of ligand molecules
might reveal interesting results. Furthermore, other drug development
techniques such as Quantitative Structure Activity Relationship (QSAR) are
more appropriate for larger data sets. Alternatively, a similar approach could be
applied to other targets in the apicoplast leading to other potential novel anti –
malarial drug candidates.
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Appendix A
Library of Analogues

Name

Structures

IUPAC name
4-oxopentyl dihydrogen phosphate

Lα
(alpha)

4-hydroxy-5-oxopentyl dihydrogen
phosphate

Lβ
(beta)

3-[formyl(hydroxy)amino]propyl
dihydrogen phosphate

Lγ
(gamma)

3-[acetyl(hydroxy)amino]propyl
dihydrogen phosphate

Lδ
(delta)

5-oxopentyl dihydrogen phosphate

Lε
(epsilon)

A1

3-hydroxy-4-oxopentyl dihydrogen
phosphate

Lζ
(zeta)

4-hydroxy-5-oxohexyl dihydrogen
phosphate

Lη
(eta)

4-oxopentylphosphonic acid

Lθ
(theta)
4-hydroxy-5-oxopentylphosphonic
acid

Lι
(iota)

4-hydroxy-5-oxohexylphosphonic
acid

Lκ
(kappa)

(1-hydroxy-5oxopentyl)phosphonic acid

Lλ
(lamda)

A2

(5-hydroxy-6-oxohexan-2yl)phosphonic acid

Lµ
(mu)

(1-hydroxy-4-methyl-5oxopentyl)phosphonic acid

Lν
(nu)

(1-hydroxy-4-methyl-5oxohexyl)phosphonic acid

Lξ
(xi)

{3-[acetyl(hydroxy)amino]-1hydroxypropyl}phosphonic acid

Lο
(omicron)

{4-[acetyl(hydroxy)amino]butan-2yl}phosphonic acid

Lπ
(pi)

2-[acetyl(hydroxy)amino]ethyl
dihydrogen phosphate

Lρ
(rho)

A3

v

2-[formyl(hydroxy)amino]ethyl
dihydrogen phosphate

Lσ
(sigma)

* L: Ligand

A4

